• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

偏头痛特异性生活质量问卷(MSQ)版本中的最小重要差异。

Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version.

作者信息

Cole J C, Lin P, Rupnow M F T

机构信息

QualityMetric, Lincoln, RI 02865-4207, USA.

出版信息

Cephalalgia. 2009 Nov;29(11):1180-7. doi: 10.1111/j.1468-2982.2009.01852.x.

DOI:10.1111/j.1468-2982.2009.01852.x
PMID:19830883
Abstract

To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention (n = 916), as well as from the QualityMetric National Headache Survey (n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses.

摘要

提出偏头痛特异性生活质量问卷2.1版(MSQ v2.1)的最小重要差异(MID)。据我们所知(截至目前),在任何人群中均不存在已发表的MSQ v2.1的MID值。对来自两项托吡酯预防偏头痛关键临床试验(n = 916)以及QualityMetric全国头痛调查(n = 1016)的数据进行了分析。分析包括基于分布和锚定的MID技术以及组水平和个体水平的MID值。组水平基于锚定的MID值范围为3.2[角色限制领域(RR)]至7.5[情绪功能领域(EF)],设定了适当MID的最低水平(这也有助于功效分析)。个体水平基于分布的MID值在两个大型数据库中得出了高度相似的估计值:RR的MID中位数为8.5,角色预防(RP)为9.2,EF为12.0。最后,个体水平基于锚定的MID值范围为5.0(RR和RP领域)至10.6(EF)。出于计算未来研究功效的组水平目的,建议RR、RP和EF的MID分别为3.2、4.6和7.5。对于使用应答者分析来分析每位患者变化的临床试验疗效的组内分析,RR需要5分。对于RP和EF,建议使用范围:RP为5.0至7.9,EF为8.0至10.6。后两个领域的MID往往存在更多误差,因此应使用范围两端的敏感性分析来确认应答者分析中的显著差异。

相似文献

1
Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version.偏头痛特异性生活质量问卷(MSQ)版本中的最小重要差异。
Cephalalgia. 2009 Nov;29(11):1180-7. doi: 10.1111/j.1468-2982.2009.01852.x.
2
Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.验证偏头痛特异性生活质量问卷 v2.1 在发作性和慢性偏头痛中的适用性。
Headache. 2012 Mar;52(3):409-21. doi: 10.1111/j.1526-4610.2011.01997.x. Epub 2011 Sep 19.
3
The impact of migraine on daily activities: effect of topiramate compared with placebo.偏头痛对日常活动的影响:托吡酯与安慰剂的疗效比较。
Curr Med Res Opin. 2006 Jun;22(6):1021-9. doi: 10.1185/030079906X104731.
4
Assessing the ability of topiramate to improve the daily activities of patients with migraine.评估托吡酯改善偏头痛患者日常活动的能力。
Mayo Clin Proc. 2006 Oct;81(10):1311-9. doi: 10.4065/81.10.1311.
5
The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials.偏头痛预防对日常活动的影响:来自三项托吡酯安慰剂对照临床试验的纵向和应答者分析。
Health Qual Life Outcomes. 2007 Oct 4;5:56. doi: 10.1186/1477-7525-5-56.
6
Topiramate improves health-related quality of life when used to prevent migraine.托吡酯用于预防偏头痛时可改善健康相关生活质量。
Headache. 2005 Sep;45(8):1023-30. doi: 10.1111/j.1526-4610.2005.05183.x.
7
The impact of topiramate on health-related quality of life indicators in chronic migraine.托吡酯对慢性偏头痛患者健康相关生活质量指标的影响。
Headache. 2007 Nov-Dec;47(10):1398-408. doi: 10.1111/j.1526-4610.2007.00950.x.
8
Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.托吡酯与阿米替林预防偏头痛的比较:一项针对成年偏头痛患者的26周多中心随机双盲双模拟平行组非劣效性试验。
Clin Ther. 2009 Mar;31(3):542-59. doi: 10.1016/j.clinthera.2009.03.020.
9
Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.偏头痛特异性生活质量问卷 2.1 电子患者报告结局在发作性和慢性偏头痛患者中的心理测量验证和有意义的患者内变化。
Headache. 2021 Mar;61(3):511-526. doi: 10.1111/head.14031. Epub 2021 Jan 22.
10
Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.托吡酯治疗慢性偏头痛:一项关于生活质量及其他疗效指标的随机、安慰剂对照试验。
Headache. 2009 Sep;49(8):1153-62. doi: 10.1111/j.1526-4610.2009.01508.x.

引用本文的文献

1
Association of Migraine Comorbidities with Quality of Life, Work Productivity and Daily Activities: Survey and Medical Claims Data in Japan.偏头痛合并症与生活质量、工作效率和日常活动的关联:日本的调查和医疗理赔数据
Adv Ther. 2025 Jun 11. doi: 10.1007/s12325-025-03236-1.
2
Behavioral interventions for migraine prevention: A systematic review and meta-analysis.偏头痛预防的行为干预措施:一项系统评价与荟萃分析。
Headache. 2025 Apr;65(4):668-694. doi: 10.1111/head.14914. Epub 2025 Feb 19.
3
Effects of electroacupuncture on treatment-resistant chronic migraine with medication overuse headache: A 12-month follow-up case report.
电针对药物过度使用性头痛所致难治性慢性偏头痛的影响:一项12个月随访病例报告。
Heliyon. 2024 Apr 28;10(9):e30417. doi: 10.1016/j.heliyon.2024.e30417. eCollection 2024 May 15.
4
Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine.评价依瑞奈玛特对慢性和发作性偏头痛患者偏头痛特异性问卷的影响。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1988-2000. doi: 10.1002/psp4.13048. Epub 2023 Oct 11.
5
Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study.日本偏头痛急性治疗效果不佳的相关结局与因素:偏头痛流行病学、治疗及护理观察性调查(OVERCOME[日本])研究结果
Drugs Real World Outcomes. 2023 Sep;10(3):415-428. doi: 10.1007/s40801-023-00368-0. Epub 2023 Jun 6.
6
The use of clinical scales and PROMs in headache disorders and migraine, summarizing their dissemination and operationalization.临床量表和患者报告结局量表在头痛疾病和偏头痛中的应用,总结其传播和实施情况。
Heliyon. 2023 May 13;9(5):e16187. doi: 10.1016/j.heliyon.2023.e16187. eCollection 2023 May.
7
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.预防性偏头痛治疗用阿替利珠单抗对 ADVANCE 随机、双盲、3 期临床试验中患者报告结局的影响。
Neurology. 2023 Feb 21;100(8):e764-e777. doi: 10.1212/WNL.0000000000201568. Epub 2022 Nov 17.
8
PROMs Following Root Canal Treatment and Surgical Endodontic Treatment.根管治疗和手术牙髓治疗后的 PROMs。
Int Dent J. 2023 Feb;73(1):28-41. doi: 10.1016/j.identj.2022.06.015. Epub 2022 Jul 21.
9
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.将偏头痛特异性生活质量映射到接受利马曲班治疗的患者的健康状态效用中。
Adv Ther. 2021 Oct;38(10):5209-5220. doi: 10.1007/s12325-021-01897-2. Epub 2021 Aug 29.
10
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.在 FOCUS 三期研究中,接受为期 6 个月的 fremanezumab 治疗后,患者的生活质量和工作效率得到改善,这些患者在接受 2 至 4 种偏头痛预防药物治疗后反应不足,为发作性和慢性偏头痛。
Headache. 2021 Oct;61(9):1376-1386. doi: 10.1111/head.14196. Epub 2021 Aug 10.